Elbasvir (MK-8742)
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 510306

CAS#: 1444832-51-2

Description: Elbasvir, also known as MK-8742, is a HCV NS5A inhibitor, which is currently in phase 2b clinical trials as part of an all-oral, interferon-free regimen for the treatment of HCV infection. The NS5A protein plays a critical role in the replication of HCV and has been the focus of numerous research efforts over the past few years. NS5A inhibitors have shown impressive in vitro potency profiles in HCV replicon assays, making them attractive components for inclusion in all oral combination regimens.


Price and Availability

Size
Price

10mg
USD 90
100mg
USD 450
1g
USD 1950
10g
USD 9650
Size
Price

25mg
USD 150
200mg
USD 650
2g
USD 2950
20g
USD 16850
Size
Price

50mg
USD 250
500mg
USD 1150
5g
USD 5650
50g
Ask price

Elbasvir (MK-8742), purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 510306
Name: Elbasvir (MK-8742)
CAS#: 1444832-51-2
Chemical Formula: C49H55N9O7
Exact Mass: 881.42245
Molecular Weight: 882.02
Elemental Analysis: C, 66.72; H, 6.29; N, 14.29; O, 12.70


Synonym: MK8742; MK-8742; MK 8742; Elbasvir.

IUPAC/Chemical Name: dimethyl ((2S,2'S)-((2S,2'S)-(((S)-6-phenyl-6H-benzo[5,6][1,3]oxazino[3,4-a]indole-3,10-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-1,2-diyl))dicarbamate

InChi Key: BVAZQCUMNICBAQ-PZHYSIFUSA-N

InChi Code: InChI=1S/C49H55N9O7/c1-27(2)41(54-48(61)63-5)45(59)56-20-10-14-37(56)43-50-25-34(52-43)30-17-19-36-32(22-30)23-39-33-18-16-31(24-40(33)65-47(58(36)39)29-12-8-7-9-13-29)35-26-51-44(53-35)38-15-11-21-57(38)46(60)42(28(3)4)55-49(62)64-6/h7-9,12-13,16-19,22-28,37-38,41-42,47H,10-11,14-15,20-21H2,1-6H3,(H,50,52)(H,51,53)(H,54,61)(H,55,62)/t37-,38-,41-,42-,47-/m0/s1

SMILES Code: O=C(N1[C@H](C2=NC=C(C3=CC=C4C(N5[C@H](C6=CC=CC=C6)OC4=C3)=CC7=C5C=CC(C8=CN=C([C@H]9N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC9)N8)=C7)N2)CCC1)[C@@H](NC(OC)=O)C(C)C


Technical Data

Appearance:
solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

  
  
 
 


References

1: Gentile I, Buonomo AR, Zappulo E, Borgia G. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? Expert Rev Anti Infect Ther. 2014 Jul;12(7):763-73. doi: 10.1586/14787210.2014.929497. PubMed PMID: 24918116.

2: Shah U, Jayne C, Chackalamannil S, Velázquez F, Guo Z, Buevich A, Howe JA, Chase R, Soriano A, Agrawal S, Rudd MT, McCauley JA, Liverton NJ, Romano J, Bush K, Coleman PJ, Grisé-Bard C, Brochu MC, Charron S, Aulakh V, Bachand B, Beaulieu P, Zaghdane H, Bhat S, Han Y, Vacca JP, Davies IW, Weber AE, Venkatraman S. Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors. ACS Med Chem Lett. 2014 Jan 9;5(3):264-9. doi: 10.1021/ml400466p. eCollection 2014 Mar 13. PubMed PMID: 24900818; PubMed Central PMCID: PMC4027630.

3: De Clercq E. Current race in the development of DAAs (direct-acting antivirals) against HCV. Biochem Pharmacol. 2014 Jun 15;89(4):441-52. doi: 10.1016/j.bcp.2014.04.005. Epub 2014 Apr 13. PubMed PMID: 24735613.

4: Mangion IK, Chen CY, Li H, Maligres P, Chen Y, Christensen M, Cohen R, Jeon I, Klapars A, Krska S, Nguyen H, Reamer RA, Sherry BD, Zavialov I. Enantioselective synthesis of an HCV NS5a antagonist. Org Lett. 2014 May 2;16(9):2310-3. doi: 10.1021/ol500971c. Epub 2014 Apr 11. PubMed PMID: 24724971.

5: Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol. 2014 Mar 21;20(11):2902-12. doi: 10.3748/wjg.v20.i11.2902. PubMed PMID: 24659881; PubMed Central PMCID: PMC3961994.

6: Coburn CA, Meinke PT, Chang W, Fandozzi CM, Graham DJ, Hu B, Huang Q, Kargman S, Kozlowski J, Liu R, McCauley JA, Nomeir AA, Soll RM, Vacca JP, Wang D, Wu H, Zhong B, Olsen DB, Ludmerer SW. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013 Dec;8(12):1930-40. doi: 10.1002/cmdc.201300343. Epub 2013 Oct 14. PubMed PMID: 24127258.